

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
Chairman & CEO: Osamu Nagayama
Inquiries to: Masahiko Uchida, General Manager,
Corporate Communications Dept.
Tel: +81-(0)3-3273-0881

**Filing of Lawsuit on Patent Infringement Concerning Oxarol[®] Ointment,
and a Petition for Provisional Disposition Order**

February 19, 2013 - Chugai Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama) (hereafter “Chugai”) announced today that it has filed a lawsuit to the Tokyo District Court as of February 19, and has also filed a petition for provisional disposition order, demanding the suspension of patent infringement related to Oxarol[®] Ointment 25 µg/g, a treatment for keratosis including psoriasis vulgaris (hereafter “Oxarol[®] Ointment”), against Iwaki Seiyaku Co., Ltd., Takata Seiyaku Co., Ltd., and Pola Pharma Inc., the distributors of the generic drugs of Oxarol[®] Ointment, as well as DKSH Japan Co., Ltd., the importer of the drug substance of said generic drugs, citing such parties’ infringement of the manufacturing process patent owned by Chugai as the ground.

Oxarol[®] Ointment is an agent for the treatment of keratosis, using active vitamin D₃ derivative maxacalcitol as an active ingredient, which Chugai has discovered. Oxarol[®] Ointment is indicated for the treatment of four diseases, namely, psoriasis vulgaris, ichthyosis, palmoplantar keratosis, and palmoplantar pustulosis.

Masahisa Yamaguchi, Department Manager of the Intellectual Property Department said, “As a company that aims at providing innovative drugs, we regard intellectual property that protects products and technologies resulted from research and development, as a very important asset. We will deal rigorously with any acts that violate it, including taking legal actions.”

Any impact resulting from these filing is negligible to Chugai's financial forecast for FY2013.